Theravance Biopharma TBPH Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's change in lease liabilities?
- Theravance Biopharma (TBPH) reported change in lease liabilities of -$2.2M in Q1 2026.
- How has Theravance Biopharma's change in lease liabilities changed year-over-year?
- Theravance Biopharma's change in lease liabilities decreased by 32.2% year-over-year, from -$1.66M to -$2.2M.
- What is the long-term trend for Theravance Biopharma's change in lease liabilities?
- Over 3 years (2021 to 2025), Theravance Biopharma's change in lease liabilities has grown at a 27.1% compound annual growth rate (CAGR), from -$3.47M to -$7.12M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.